ArticleFrontiers in immunology2026
The role of R-loop aberrations in lower-grade gliomas: prognostic, immune, and metabolic implications from multi-omics and machine learning analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic and therapeutic implications of R-loop regulators in lower-grade glioma (LGG) remain largely unexplored. Methods: We constructed a R-loop prognostic index (RLPI) by benchmarking 9 machine-learning algorithms through nested cross-validation. Associations between RLPI and clinical outcomes, immune microenvironment, and metabolic features were assessed across -11 bulk transcriptomic, 2 single-cell RNA-sequencing, and 1 spatial transcriptomic LGG cohorts. Functional validation was performed for key RLPI genes. Results: Among the 9 algorithms tested, Elastic Net demonstrated the best predictive performance and was selected to construct the RLPI, which comprised 35 R-loop regulators. Elevated RLPI robustly predicted poorer prognosis in 1556 patients across 6 independent LGG cohorts. High-RLPI glioma cells were enriched in angiogenesis and hypoxia pathways and exhibited a mesenchymal-like state with heightened metabolic activity. Notably, RLPI correlated with enhanced antigen presentation and immunosuppressive signaling, alongside increased infiltration of immune cells with pro- or anti-tumor functions. Moreover, high RLPI correlated with resistance to radiotherapy and temozolomide but improved response to immune checkpoint blockade therapy. Functional assays revealed that knockdown of INCENP suppressed glioma cell proliferation, migration, and invasion while promoting apoptosis, whereas NCAPG silencing impaired migration and invasion. Conclusion: This study establishes the RLPI as a promising biomarker for personalized risk stratification and treatment guidance in LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.